Idt Australia Limited · ASX:IDT
Idt Australia — Shareholder Meeting (November 2015)
9 slides from Idt Australia's shareholder meeting presentation, Nov 19, 2015
Slide 1: 2015 AGM: 2015 Milestones, how did we do?
11/19/2015 For personal use only 2015 AGM TARGETED 2015 MILESTONES, how did we do? INCREASED 2014/15 ORGANIC SALES TOWARDS PROFITABILITY MOVEMENT OF AN ADDITIONAL INTERNAL PRODUCT TOWARDS MARKET ACQUISITION OF APPROVED PRODUCTS FOR MAJOR MARKETS MOVE FROM SERVICE PROVIDER, TOWARDS SPECIALTY GENERIC
Slide 2: Highlights of the Past Year / Financially Positioned to Deliver
11/19/2015 HIGHLIGHTS OF THE PAST YEAR For personal use only ACQUISITIONOF GENERIC US DRUG PORTFOLIO ANI appointed to distribute first 18 in US, Mayne to distribute TMZ Transformative step for the company, aiming for rapid return to profitability BUILDING IN-HOUSE DRUG PORTFOLIO Filed first IDT ANDA
Slide 3: 2014/15 Results
11/19/2015 2014/15 For personal use only RESULTS FY15(A) 20,000.0 15,000.0 10,000.0 CMAX Sales Boronia Sales Total Sales Revenue 5,000.0 Profit before tax - CMAX Sales Boronia Sales Total Sales Revenue Profit before tax -5,000.0 www.idtaus.com.au 5 2014/15 RESULTS Company Performance FY14 vs FY15 20
Slide 4: 2014/15 Year on Year Comparison / IDT Group Sales Organic Growth
11/19/2015 2014/15 For personal use only YEAR ON YEAR COMPARISON 20,000.0 15,000.0 10,000.0 FY14 (A) 5,000.0 FY15(A) - CMAX Sales Boronia Sales Total Sales Revenue Profit before tax -5,000.0 -10,000.0 www.idtaus.com.au 7 IDT GROUP SALES ORGANIC GROWTH 12,000 Revenue, by Half Year ($000) 10,000 8,000
Slide 5: Manufacturing Sales Pipeline Growth / IDT Specialty Generic Strategy
11/19/2015 MANUFACTURING SALES PIPELINE GROWTH For personal use only Boronia Sales Pipeline ($000) 60,000 50,000 40,000 30,000 20,000 10,000 0 Jun-13 Dec-13 Jun-14 Dec-14 Jun-15 Nov-15 www.idtaus.com.au 9 IDT SPECIALTY GENERIC STRATEGY GENERIC DRUG PORTFOLIO • Purchased 23 approved drugs Dec2014, no
Slide 6: IDT Product Portfolio
11/19/2015 IDT PRODUCT PORTFOLIO For personal use only Product Dose Form Indication Class Aminophylline Tablet Asthma Respiratory Carbidopa & Levodopa Tablet Parkinson's Disease Neurology Ciprofloxacin Tablet Bacterial Infections Infectious Disease Clarithromycin ER Tablet Bacterial Infections Infec
Slide 7: US Market Portfolio Re-launch Process / US Distribution Partnerships
11/19/2015 US MARKET PORTFOLIO RE-LAUNCH PROCESS For personal use only • Initial cohort of CBE30 products followed by PAS approvals • Many niche products with low to moderate competition • Products all long genericized with established markets – predictable volumes & pricing, little risk of new comp
Slide 8: CMAX New Facility Progress / Board & Management Strengthened
11/19/2015 CMAX NEW FACILITY PROGRESS For personal use only • Build complete and fit-out commenced • On time and on budget to date • Move scheduled for April 2016 • Will be the largest, newest, facility in Australia with capacity for expansion and a strong forward sales book • Adjacent new medical r
Slide 9: Target 2016 Milestones / Questions and Answers
11/19/2015 TARGET 2016 MILESTONES For personal use only INCREASED ORGANIC SALES TOWARDS PROFITABILITY SUCCESSFUL RE-LOCATION OF CMAX FURTHER IN HOUSE AND ACQUIRED PORTFOLIO DEELOPMENT FINANCING TO MAXIMISE PROGRESS WITH LAUNCH/RE-LAUNCH OF US GENERIC PORTFOLIO EXPLORE AND PROGRESS PRODUCT COMERCIALI